Maravai (MRVI): Price-to-Projected Revenue Ratio

Brandmark of Maravai LifeSciences Corp (MRVI)

The estimated forward P/S reflects market expectations, where the 5.20 level captures the current state. Maravai LifeSciences (MRVI) acts as a biomedicine pioneer, creating benchmark components for gene therapy. Demand for its products is non-cyclical and crisis-resistant. Meanwhile, business success relies on the volume of laboratory investments in equipment, which necessitates close monitoring of margins.

Maravai LifeSciences Holdings - MRVI Forward P/S Multiple (period 07/04/2022 - 11/17/2026)

Metric breakdowns and analytics for Maravai LifeSciences (MRVI)

Comprehensive company analysis:Maravai LifeSciences Corp (MRVI)
Product sample of Maravai

Maravai LifeSciences dominance in mRNA synthesis, driven by CleanCap patents, ensures a steady revenue stream. This cash flow serves as the foundation for calculating the forward P/S ratio, which compares the market value of shares to projected sales volume. The indicator determines the extent of the asset's overvaluation, eliminating subjective assessments and relying on financial facts. Analyzing forward capitalization to revenue allows for the identification of inflated multiplier risks and the optimization of the portfolio.

Key competitors

Forward P/S Multiple A (agilent.com)|Quest Corp (DGX) - Market Cap to Future Revenue Ratio|ILMN - Price-to-Projected Revenue Ratio|EXAS - Forward P/S Multiple|RVTY (Revvity) - Forward Price-to-Revenue Multiple|Bio-Rad - Forward Price to Sales|Price-to-Projected Revenue Ratio anbio.com|Forward P/S Multiple Sotera Health Company|Price-to-Projected Revenue Ratio QuidelOrtho (QDEL)|OPK - Market Cap to Future Revenue Ratio|caredx.com - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio FLGT (Fulgent Corp)|LAB: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Cytek Corp CTKB|OSUR (OraSure Technologies Inc) - Forward Price-to-Revenue Multiple|Forward Price-to-Revenue Multiple Exagen Inc.|Forward Price-to-Revenue Multiple MDXH|LUCD - Projected Price to Revenue|Price-to-Projected Revenue Ratio Prenetics (PRE)|Price-to-Projected Revenue Ratio IMDX (Insight Molecular Diagnostics Inc)|Trinity Biotech - Forward Price-to-Revenue Multiple|prophaselabs.com - Price-to-Projected Revenue Ratio|AIMD - Price-to-Projected Revenue Ratio|Co-Diagnostics Inc (CODX) - Forward Price-to-Revenue Multiple|HSCS: Forward P/S Multiple|BMRA - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple CDIO|Market Cap to Future Revenue Ratio onconetix.gcs-web.com ONCO|Price-to-Projected Revenue Ratio Virax Biolabs (VRAX)|Price to Expected Revenue Ratio BJDX|Price-to-Projected Revenue Ratio Vermillion AWH|Accelerate Diagnostics Inc (AXDX) - Market Cap to Future Revenue Ratio|centogene.com - Forward P/S Multiple|ENZ (Enzo Biochem Inc.) - Market Cap to Projected Revenue|Market Cap to Future Revenue Ratio FRES|Market Cap to Future Revenue Ratio GTG Labs (GENE)|ME (23andme.com) - Forward P/S Multiple|Forward P/S Multiple Psychemedics Inc